"Collection of Gene Mutations for Laboratory Quality Assurance” Newborn Screening Accuracy Project,
Role: PI,
Centers for Disease Control and Prevention/DHHS,
(09/2024 - 09/2025)
Status: Approved
"Newborn screening for cystic fibrosis in California" including Phase A: "Development of cystic Fibrosis newborn screening strategies for multiethnic populations" and Phase B: "Cystic fibrosis mutation frequencies among Hispanics",
Role: PI,
Health Resources and Services Administration/DHHS,
Status: Completed
For Profit Organization
A phase 3, rollover study to evaluate the safety and efficacy of long-term treatment with lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation (Vertex study number: VX12-809-105),
Role: Investigator,
Vertex Pharmaceuticals Incorporated (Vertex),
(01/2016 - 01/2017)
Status: Completed
A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 12 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation,
Role: Investigator,
Vertex Pharmaceuticals Incorporated (Vertex),
(05/2014 - 05/2015)
Status: Completed
Internal
Awareness of anaphylaxis in preschools,
Role: Investigator,
LLU Dept. of Pediatrics,
(01/2008)
Status: Completed
Non-Profit Organization
Cystic Fibrosis Foundation Care Centers,
Role: Co-Investigator,
Cystic Fibrosis Foundation,
(07/2018 - 06/2019)
Status: Closed